Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 18/20 | 0.48 |
| ▸ | KAT7 | O95251 | 15/20 | 0.48 |
| ▸ | KAT6B | Q8WYB5 | 9/20 | 0.44 |
| ▸ | KAT5 | Q92993 | 5/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 5/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30360821 | 1.00 | KAT6A (0.48) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL25562267 | 0.95 | KAT6A (0.49) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL30360809 | 0.95 | KAT6A (0.49) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL25562126 | 0.92 | KAT6A (0.53) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL30360831 | 0.92 | KAT6A (0.53) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL25562269 | 0.88 | KAT6A (0.45) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL30360857 | 0.88 | KAT6A (0.45) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL30360835 | 0.87 | KAT6A (0.55) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL25561774 | 0.87 | KAT6A (0.55) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL25562903 | 0.87 | KAT6A (0.46) | KAT6AKAT7KAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150374-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-05-09 | — | — | US | disclosed |
| US-20240109880-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (HK) | 2024-04-04 | — | — | US | disclosed |
| WO-2023088233-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150374-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | KAT6A, KAT2A, KAT6B | KAT6A 1/4885KAT7 5/4885KAT6B 3/4885 |
| US-20240109880-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | KAT6A, KAT2A, KAT6B | KAT6A 1/4885KAT7 5/4885KAT6B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.